Ims Health Holdings Inc (IMS) 27.22 $IMS
Kindred Announces Appointment of Dr. Sharad Mansukani to Board of Directors
Business Wire - Thu Oct 29, 4:00PM CDT
Kindred Healthcare, Inc. ("Kindred" or the "Company"
(NYSE:KND) today announced that its Board of Directors has appointed Dr. Sharad Mansukani to the Board effective immediately.
CI: 134.04 (-1.51), KND: 13.40 (+0.13), IMS: 27.22 (-1.23), SCAI: 29.61 (+0.04)
IMS Health tops 3Q profit forecasts
Automated Insights - Thu Oct 29, 7:05AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Thursday reported third-quarter earnings of $43 million.
IMS: 27.22 (-1.23)
IMS Health Reports Third-Quarter 2015 Results
Business Wire - Thu Oct 29, 6:00AM CDT
--Adjusted EBITDA up 8.6 percent at constant currency
IMS: 27.22 (-1.23)
IDC MarketScape Names IMS Health a Global Leader in Life Sciences Sales and Marketing Outsourcing
Business Wire - Tue Oct 27, 7:00AM CDT
IMS Health (NYSE:IMS) has been named a global leader in IDC Health Insights' annual assessment of sales and marketing business process outsourcing (BPO) services available to the life sciences industry. The report, IDC MarketScape: Worldwide Life Science Sales and Marketing BPO 2015 Vendor Assessment (doc #HI258820, September 2015), cites IMS Health's extensive industry expertise relative to other vendors and gives the company high marks for its technical skills.
IMS: 27.22 (-1.23)
Quintiles and IMS Health Announce Global Collaboration to Advance the Use of Next-Generation Real-World Evidence in Late-Stage Clinical Research
Business Wire - Thu Oct 22, 5:45AM CDT
Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-stage clinical research. With complementary strengths in real-world data management, operational delivery, advanced analytics, and scientific and therapeutic expertise, the collaboration will accelerate assessments of treatment impact and help improve patient outcomes.
IMS: 27.22 (-1.23), Q: 63.65 (-0.82)
IMS Health to Announce Third-Quarter 2015 Results On October 29, 2015
Business Wire - Thu Oct 15, 3:15PM CDT
IMS Health Holdings, Inc. ("IMS Health" (NYSE:IMS) will issue its third-quarter 2015 financial results before the market opens on Thursday, October 29, 2015. The earnings release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com.
IMS: 27.22 (-1.23)
4 Pharma Stocks Gaining from High Pricing Power
Swarup Gupta - Zacks Investment Research - Tue Oct 06, 10:05AM CDT
A new study shows that higher revenue generated by pharma companies is primarily attributable to a series of price increases.
BIIB: 290.51 (-3.21), IMS: 27.22 (-1.23), CVS: 98.78 (-5.02), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), TEVA: 59.19 (-1.05), LLY: 81.57 (-0.43), NVS: 90.43 (-0.53)
IMS Health Named a Leader for Worldwide Sales and Marketing IT Outsourcing by IDC MarketScape
Business Wire - Wed Sep 30, 8:00AM CDT
IMS Health (NYSE:IMS) has been named a leader in the IDC MarketScape: Worldwide Life Science Sales and Marketing ITO 2015 Vendor Assessment (doc # HI258425, August 2015). According to the IDC MarketScape assessment, "Relative to other vendors discussed in this report and based on feedback from multiple customer references, IMS Health was rated highly for life science-specific industry expertise and for its technical skills.... IMS Health has experience working with life science companies across all three sections of the industry: pharmaceutical, biotech and medical devices."
IMS: 27.22 (-1.23)
Information Technology Services Equities Scrutiny -- Xerox, International Business Machines, CDW Corp., IMS Health Holdings and Computer Sciences
PR Newswire - Wed Sep 23, 7:18AM CDT
Equity Research Institute has initiated coverage on the following equities: Xerox Corporation (NYSE: XRX), International Business Machines Corporation (NYSE: IBM), CDW Corporation (NASDAQ: CDW), IMS Health Holdings Inc. (NYSE: IMS) and Computer Sciences Corporation (NYSE: CSC). Free research report on Xerox can be accessed at https://www.erionline.net/XRX.pdf. On Tuesday, September 22, 2015, the NASDAQ Composite ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average lost 1.09%, to finish the day at 16,330.47 and the S&P 500 closed at 1,942.74, down 1.23%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IMS: 27.22 (-1.23), CSC: 66.59 (+0.41), IBM: 140.08 (-0.47), XRX: 9.39 (+0.05), CDW: 44.69 (-0.05)
Amgen's 2018 Repatha Sales Estimates Hiked 60%
at Investor's Business Daily - Tue Sep 22, 1:30PM CDT
The bull case for Amgen's (AMGN) new cholesterol drug Repatha continued to be built Tuesday, as Nomura raised long-term estimates on the drug's sales while UBS defended its optimistic thesis for both Repatha and rival drug Praluent, from Sanofi (SNY)...
IMS: 27.22 (-1.23), AMGN: 158.18 (-2.40), SNY: 50.34 (+0.71), REGN: 557.39 (-2.63), NVS: 90.43 (-0.53)
IMS Health Study: Patient Options Expand as Mobile Healthcare Apps Address Wellness and Chronic Disease Treatment Needs
Business Wire - Thu Sep 17, 7:00AM CDT
--Connectivity to Sensors and Wearables Drive Use
IMS: 27.22 (-1.23)
IMS Health Announces Next Generation Multichannel Solution Nexxus Mobile Intelligence 11
Business Wire - Mon Aug 24, 7:00AM CDT
IMS Health (NYSE:IMS) today announced the immediate availability of Nexxus(TM) Mobile Intelligence 11, the latest generation of its cloud-based CRM solution designed specifically for the Life Sciences industry.
IMS: 27.22 (-1.23)
IMS Health Launches Global Thought Leadership Mobile App
Business Wire - Thu Aug 20, 7:00AM CDT
IMS Health (NYSE:IMS) today announced the immediate availability of IMS Health Insights -- a free application that delivers the company's extensive thought leadership materials from 19 major countries directly to Apple and Android tablet devices.
IMS: 27.22 (-1.23)
Endo Q2 Earnings Beat Estimates, But Guidance On Hold
at Investor's Business Daily - Mon Aug 10, 5:24PM CDT
Specialty-drug maker and IBD 50 stock Endo International beat Wall Street's Q2 expectations Monday, but didn't change its guidance as it digests a major acquisition. Endo (ENDP) stock fell as much as 4.6% early Monday but ended the day up a fraction...
ENDP: 59.99 (-0.39), IMS: 27.22 (-1.23), MYL: 44.09 (-1.69)
IMS Health Announces Launch of Secondary Public Offering Of Common Stock
Business Wire - Wed Aug 05, 3:35PM CDT
IMS Health Holdings, Inc. ("IMS Health" (NYSE:IMS) today announced the launch of an underwritten, secondary public offering of 20,000,000 shares of its common stock by certain of its existing shareholders affiliated with TPG Global, LLC, Canada Pension Plan Investment Board and Leonard Green & Partners, L.P. (the "Selling Shareholders" . IMS Health is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders.
IMS: 27.22 (-1.23), JPM: 64.25 (-0.96)
IMS Health beats Street 2Q forecasts
Automated Insights - Fri Jul 31, 6:15AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Friday reported second-quarter net income of $47 million, after reporting a loss in the same period a year earlier.
IMS: 27.22 (-1.23)
IMS Health Reports Second-Quarter 2015 Results
Business Wire - Fri Jul 31, 6:00AM CDT
--Adjusted EBITDA up 9.5 percent at constant currency
IMS: 27.22 (-1.23)
IMS Health to Announce Second-Quarter 2015 Results on July 31, 2015
Business Wire - Thu Jul 23, 3:05PM CDT
IMS Health Holdings, Inc. ("IMS Health" (NYSE:IMS) will issue its second-quarter 2015 financial results before the market opens on Friday, July 31, 2015. The press release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com.
IMS: 27.22 (-1.23)
J&J Earnings Beat Views As Pharma Leads Way Again
at Investor's Business Daily - Tue Jul 14, 10:18AM CDT
Medical giant Johnson & Johnson (JNJ) beat Wall Street's Q2 estimates and lifted its guidance Tuesday, but the stock was off a fraction in early trading as revenue declined. Earnings excluding special items shrank 4% from the year-earlier quarter to...
JNJ: 101.03 (-0.34), IMS: 27.22 (-1.23), MDT: 73.92 (+0.16), GMED: 22.35 (-0.09), GILD: 108.13 (-1.08), STJ: 63.81 (+0.23), ABBV: 59.55 (+5.45)
IMS Health and Foundation Med collaborate on understanding effectiveness of precision cancer therapies
Seeking Alpha - at Seeking Alpha - Mon Jun 22, 9:37AM CDT
IMS: 27.22 (-1.23), FMI: 22.42 (+0.26)
Kindred Announces Appointment of Dr. Sharad Mansukani to Board of Directors
Business Wire - Thu Oct 29, 4:00PM CDT
Kindred Healthcare, Inc. ("Kindred" or the "Company"
(NYSE:KND) today announced that its Board of Directors has appointed Dr. Sharad Mansukani to the Board effective immediately. CI: 134.04 (-1.51), KND: 13.40 (+0.13), IMS: 27.22 (-1.23), SCAI: 29.61 (+0.04)
IMS Health tops 3Q profit forecasts
Automated Insights - Thu Oct 29, 7:05AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Thursday reported third-quarter earnings of $43 million.
IMS: 27.22 (-1.23)
IMS Health Reports Third-Quarter 2015 Results
Business Wire - Thu Oct 29, 6:00AM CDT
--Adjusted EBITDA up 8.6 percent at constant currency
IMS: 27.22 (-1.23)
IDC MarketScape Names IMS Health a Global Leader in Life Sciences Sales and Marketing Outsourcing
Business Wire - Tue Oct 27, 7:00AM CDT
IMS Health (NYSE:IMS) has been named a global leader in IDC Health Insights' annual assessment of sales and marketing business process outsourcing (BPO) services available to the life sciences industry. The report, IDC MarketScape: Worldwide Life Science Sales and Marketing BPO 2015 Vendor Assessment (doc #HI258820, September 2015), cites IMS Health's extensive industry expertise relative to other vendors and gives the company high marks for its technical skills.
IMS: 27.22 (-1.23)
Quintiles and IMS Health Announce Global Collaboration to Advance the Use of Next-Generation Real-World Evidence in Late-Stage Clinical Research
Business Wire - Thu Oct 22, 5:45AM CDT
Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-stage clinical research. With complementary strengths in real-world data management, operational delivery, advanced analytics, and scientific and therapeutic expertise, the collaboration will accelerate assessments of treatment impact and help improve patient outcomes.
IMS: 27.22 (-1.23), Q: 63.65 (-0.82)
IMS Health to Announce Third-Quarter 2015 Results On October 29, 2015
Business Wire - Thu Oct 15, 3:15PM CDT
IMS Health Holdings, Inc. ("IMS Health"
(NYSE:IMS) will issue its third-quarter 2015 financial results before the market opens on Thursday, October 29, 2015. The earnings release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com. IMS: 27.22 (-1.23)
4 Pharma Stocks Gaining from High Pricing Power
Swarup Gupta - Zacks Investment Research - Tue Oct 06, 10:05AM CDT
A new study shows that higher revenue generated by pharma companies is primarily attributable to a series of price increases.
BIIB: 290.51 (-3.21), IMS: 27.22 (-1.23), CVS: 98.78 (-5.02), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), TEVA: 59.19 (-1.05), LLY: 81.57 (-0.43), NVS: 90.43 (-0.53)
IMS Health Named a Leader for Worldwide Sales and Marketing IT Outsourcing by IDC MarketScape
Business Wire - Wed Sep 30, 8:00AM CDT
IMS Health (NYSE:IMS) has been named a leader in the IDC MarketScape: Worldwide Life Science Sales and Marketing ITO 2015 Vendor Assessment (doc # HI258425, August 2015). According to the IDC MarketScape assessment, "Relative to other vendors discussed in this report and based on feedback from multiple customer references, IMS Health was rated highly for life science-specific industry expertise and for its technical skills.... IMS Health has experience working with life science companies across all three sections of the industry: pharmaceutical, biotech and medical devices."
IMS: 27.22 (-1.23)
Information Technology Services Equities Scrutiny -- Xerox, International Business Machines, CDW Corp., IMS Health Holdings and Computer Sciences
PR Newswire - Wed Sep 23, 7:18AM CDT
Equity Research Institute has initiated coverage on the following equities: Xerox Corporation (NYSE: XRX), International Business Machines Corporation (NYSE: IBM), CDW Corporation (NASDAQ: CDW), IMS Health Holdings Inc. (NYSE: IMS) and Computer Sciences Corporation (NYSE: CSC). Free research report on Xerox can be accessed at https://www.erionline.net/XRX.pdf. On Tuesday, September 22, 2015, the NASDAQ Composite ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average lost 1.09%, to finish the day at 16,330.47 and the S&P 500 closed at 1,942.74, down 1.23%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
IMS: 27.22 (-1.23), CSC: 66.59 (+0.41), IBM: 140.08 (-0.47), XRX: 9.39 (+0.05), CDW: 44.69 (-0.05)
Amgen's 2018 Repatha Sales Estimates Hiked 60%
at Investor's Business Daily - Tue Sep 22, 1:30PM CDT
The bull case for Amgen's (AMGN) new cholesterol drug Repatha continued to be built Tuesday, as Nomura raised long-term estimates on the drug's sales while UBS defended its optimistic thesis for both Repatha and rival drug Praluent, from Sanofi (SNY)...
IMS: 27.22 (-1.23), AMGN: 158.18 (-2.40), SNY: 50.34 (+0.71), REGN: 557.39 (-2.63), NVS: 90.43 (-0.53)
IMS Health Study: Patient Options Expand as Mobile Healthcare Apps Address Wellness and Chronic Disease Treatment Needs
Business Wire - Thu Sep 17, 7:00AM CDT
--Connectivity to Sensors and Wearables Drive Use
IMS: 27.22 (-1.23)
IMS Health Announces Next Generation Multichannel Solution Nexxus Mobile Intelligence 11
Business Wire - Mon Aug 24, 7:00AM CDT
IMS Health (NYSE:IMS) today announced the immediate availability of Nexxus(TM) Mobile Intelligence 11, the latest generation of its cloud-based CRM solution designed specifically for the Life Sciences industry.
IMS: 27.22 (-1.23)
IMS Health Launches Global Thought Leadership Mobile App
Business Wire - Thu Aug 20, 7:00AM CDT
IMS Health (NYSE:IMS) today announced the immediate availability of IMS Health Insights -- a free application that delivers the company's extensive thought leadership materials from 19 major countries directly to Apple and Android tablet devices.
IMS: 27.22 (-1.23)
Endo Q2 Earnings Beat Estimates, But Guidance On Hold
at Investor's Business Daily - Mon Aug 10, 5:24PM CDT
Specialty-drug maker and IBD 50 stock Endo International beat Wall Street's Q2 expectations Monday, but didn't change its guidance as it digests a major acquisition. Endo (ENDP) stock fell as much as 4.6% early Monday but ended the day up a fraction...
ENDP: 59.99 (-0.39), IMS: 27.22 (-1.23), MYL: 44.09 (-1.69)
IMS Health Announces Launch of Secondary Public Offering Of Common Stock
Business Wire - Wed Aug 05, 3:35PM CDT
IMS Health Holdings, Inc. ("IMS Health"
(NYSE:IMS) today announced the launch of an underwritten, secondary public offering of 20,000,000 shares of its common stock by certain of its existing shareholders affiliated with TPG Global, LLC, Canada Pension Plan Investment Board and Leonard Green & Partners, L.P. (the "Selling Shareholders" . IMS Health is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders. IMS: 27.22 (-1.23), JPM: 64.25 (-0.96)
IMS Health beats Street 2Q forecasts
Automated Insights - Fri Jul 31, 6:15AM CDT
DANBURY, Conn. (AP) _ IMS Health Holdings Inc. (IMS) on Friday reported second-quarter net income of $47 million, after reporting a loss in the same period a year earlier.
IMS: 27.22 (-1.23)
IMS Health Reports Second-Quarter 2015 Results
Business Wire - Fri Jul 31, 6:00AM CDT
--Adjusted EBITDA up 9.5 percent at constant currency
IMS: 27.22 (-1.23)
IMS Health to Announce Second-Quarter 2015 Results on July 31, 2015
Business Wire - Thu Jul 23, 3:05PM CDT
IMS Health Holdings, Inc. ("IMS Health"
(NYSE:IMS) will issue its second-quarter 2015 financial results before the market opens on Friday, July 31, 2015. The press release and accompanying financial information will be posted on the IMS Health Investor Relations website at http://ir.imshealth.com. IMS: 27.22 (-1.23)
J&J Earnings Beat Views As Pharma Leads Way Again
at Investor's Business Daily - Tue Jul 14, 10:18AM CDT
Medical giant Johnson & Johnson (JNJ) beat Wall Street's Q2 estimates and lifted its guidance Tuesday, but the stock was off a fraction in early trading as revenue declined. Earnings excluding special items shrank 4% from the year-earlier quarter to...
JNJ: 101.03 (-0.34), IMS: 27.22 (-1.23), MDT: 73.92 (+0.16), GMED: 22.35 (-0.09), GILD: 108.13 (-1.08), STJ: 63.81 (+0.23), ABBV: 59.55 (+5.45)
IMS Health and Foundation Med collaborate on understanding effectiveness of precision cancer therapies
Seeking Alpha - at Seeking Alpha - Mon Jun 22, 9:37AM CDT
IMS: 27.22 (-1.23), FMI: 22.42 (+0.26)
